Eli Lilly to Acquire Loxo Oncology for $8B

 Eli Lilly to Acquire Loxo Oncology for $8B

Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

  • Eli Lily acquires Loxo Oncology, in all stock transaction for $8B. Loxo to receive $235/share in cash making $8B as total deal value, including premium based on its last day closing share price value
  • The focus of the acquisition is to utilize Loxo’s approved oncology portfolio for patients with genomically defined cancers. The acquisition is expected to close in Q1’19
  • Vitrakvi is an oral TRK inhibitor developed in collaboration with Bayer, targeted for specific genetic abnormality and has also received FDA approval. LOXO-292 is an oral RET inhibitor indicated for targeting cancers with alterations to the rearranged during transfection (RET) kinase. LOXO-305 & LOXO-195 is an oral P-I/II BTK & TRK inhibitor respectively

Click here to read full press release/ article | Ref: Lilly | Image: E15


Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post